Home › Funds › ASSETMARK, INC › UTHR
ASSETMARK, INC position in UTHR
UNITED THERAPEUTICS CORP DEL · Health Care
ASSETMARK, INC reported holding 600,171 shares of UTHR (UNITED THERAPEUTICS CORP DEL) in its Q3 2026 13F filing — a position valued at US$325.2M, representing 0.55% of its reported portfolio and ranking #40 among its reported holdings. ASSETMARK, INC has disclosed UTHR holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How ASSETMARK, INC's UTHR position evolved
ASSETMARK, INC first disclosed a stake in UTHR in Q3 2023 at 270,228 shares (US$61.0M). The position peaked in Q1 2026 at 616,050 shares, worth US$365.3M. Across 13 filings, ASSETMARK, INC increased the stake 6 time(s), trimmed it 6 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 600,171 shares valued at US$325.2M — a reduction of -23,897 shares quarter over quarter.. Notable position changes include a 57% increase in Q3 2024 (shares fell 2% over the following quarter), a 38% increase in Q2 2025 (shares rose 46% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 270.23K | $61.04M | New |
| Q4 2023 | 272.32K | $59.88M | Add |
| Q1 2024 | 270.16K | $62.06M | Reduce |
| Q2 2024 | 267.71K | $85.28M | Reduce |
| Q3 2024 | 419.96K | $150.49M | Add |
| Q4 2024 | 429.16K | $151.42M | Add |
| Q1 2025 | 518.45K | $159.82M | Add |
| Q2 2025 | 715.83K | $205.69M | Add |
| Q3 2025 | 645.91K | $270.77M | Reduce |
| Q4 2025 | 634.96K | $309.38M | Reduce |
| Q1 2026 | 616.05K | $365.31M | Reduce |
| Q2 2026 | 624.07K | $338.14M | Add |
| Q3 2026 | 600.17K | $325.23M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About UTHR and 13F data
UTHR (UNITED THERAPEUTICS CORP DEL) is a Health Care company. 38 other funds we track also report a position in UTHR — the largest reported positions include Avoro Capital Advisors LLC (US$1.51B), Renaissance Technologies (US$908.2M), DEERFIELD MANAGEMENT COMPANY, L.P. (US$247.6M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding UTHR
- Avoro Capital Advisors LLC 2.78M sh · $1.51B · Q2 2026
- Renaissance Technologies 1.68M sh · $908.15M · Q3 2026
- DEERFIELD MANAGEMENT COMPANY, L.P. 457.00K sh · $247.62M · Q2 2026
- Vestal Point Capital, LP 435.00K sh · $235.70M · Q2 2026
- Eversept Partners, LP 287.67K sh · $155.87M · Q2 2026
More on ASSETMARK, INC
FAQ
How long has ASSETMARK, INC held UTHR?
ASSETMARK, INC has disclosed UTHR holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
What is ASSETMARK, INC's current position in UTHR?
As of Q3 2026, ASSETMARK, INC holds 600.17K shares of UTHR (UNITED THERAPEUTICS CORP DEL), valued at $325.23M, representing 0.55% of its reported portfolio and ranking #40.
Has ASSETMARK, INC been buying or selling UTHR?
In the latest 13F filing (Q3 2026), ASSETMARK, INC reduced its position in UTHR. The position peaked in Q1 2026 at 616.05K shares.
Which other funds hold UTHR?
Other major institutional holders of UTHR include Avoro Capital Advisors LLC, Renaissance Technologies, DEERFIELD MANAGEMENT COMPANY, L.P., among 38 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.